EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases

John S Schardt, Neelan S Sivaneri, Peter M Tessier

BioDrugs · 2024-07 · 38 (4) · 477-486

DOI: 10.1007/s40259-024-00667-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 02.07.2024. Verfasst von John S Schardt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, B-Lymphocytes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The screening of antigen-specific B cells has been pivotal for biotherapeutic development for over four decades. Conventional antibody discovery strategies, including hybridoma technology and single B cell screening, remain widely used based on their simplicity, accessibility, and proven track record. Technological advances and the urgent demand for infectious disease applications have shifted paradigms in single B cell screening, resulting in increased throughput and decreased time and labor, ultimately enabling the rapid identification of monoclonal antibodies with desired biological and biophysical properties. Herein, we provide an overview of conventional and emergent single B cell screening approaches and highlight their potential strengths and weaknesses. We also detail the impact of innovative technologies-including miniaturization, microfluidics, multiplexing, and deep sequencing-on the recent identification of broadly neutralizing antibodies for infectious disease applications. Overall, the coronavirus disease 2019 (COVID-19) pandemic has reinvigorated efforts to improve the efficiency of monoclonal antibody discovery, resulting in the broad application of innovative antibody discovery methodologies for treating a myriad of infectious diseases and pathological conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalB-LymphocytesHumansCOVID-19SARS-CoV-2AnimalsSingle-Cell AnalysisAntibodies, NeutralizingCommunicable DiseasesCOVID-19 Drug Treatment

Substanzen

Antibodies, MonoclonalAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA. ptessier@umich.edu.
  • Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA. ptessier@umich.edu.
  • Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA. ptessier@umich.edu.

Förderung

  • NIGMS NIH HHS
  • NIA NIH HHS
  • NINDS NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • National Institute of General Medical Sciences
  • National Institute on Aging
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Schardt, J. S., Sivaneri, N. S., & Tessier, P. M. (2024). Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases. BioDrugs, 38(4), 477-486. https://doi.org/10.1007/s40259-024-00667-0

Vancouver

Schardt JS, Sivaneri NS, Tessier PM. Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases. BioDrugs. 2024;38(4):477-486. doi:10.1007/s40259-024-00667-0

BibTeX
@article{Schardt2024,
  author = {Schardt, John S and Sivaneri, Neelan S and Tessier, Peter M},
  title = {Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases},
  journal = {BioDrugs},
  year = {2024},
  volume = {38},
  number = {4},
  pages = {477--486},
  doi = {10.1007/s40259-024-00667-0}
}
Kostenlos starten →